Imagion Biosystems Limited (ASX: IBX) (the Company), a company dedicated to improving healthcare through the earlier detection of cancer, is pleased to announce that it has successfully completed the placement of the shortfall shares under its recent 1-for-2 pro-rata non-renounceable rights issue offer (Rights Issue).
The Company has raised a total of $4.3 million (before costs) under the Rights Issue offer and shortfall placement.
The shortfall placement, which was lead managed by Pamplona Corporate Pty Ltd (Lead Manager), was fully subscribed by sophisticated and professional investors.
View the announcement, “Imagion Biosystems Raises $4.3M Via Rights Issue.”